News articles about Portola Pharmaceuticals (NASDAQ:PTLA) have trended somewhat positive on Sunday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Portola Pharmaceuticals earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 47.386989767972 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news headlines that may have effected Accern Sentiment’s analysis:

A number of equities research analysts recently weighed in on PTLA shares. BidaskClub raised shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday. ValuEngine downgraded shares of Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. William Blair reaffirmed a “buy” rating on shares of Portola Pharmaceuticals in a research note on Thursday, March 1st. Morgan Stanley downgraded shares of Portola Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $65.00 target price for the company. in a research note on Thursday, March 1st. Finally, Oppenheimer set a $67.00 target price on shares of Portola Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, March 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. Portola Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $64.90.

Shares of Portola Pharmaceuticals (NASDAQ:PTLA) opened at $38.43 on Friday. Portola Pharmaceuticals has a 12 month low of $30.10 and a 12 month high of $67.10. The company has a quick ratio of 5.92, a current ratio of 5.94 and a debt-to-equity ratio of 0.30. The company has a market cap of $2,470.00, a P/E ratio of -8.06 and a beta of 1.33.

Portola Pharmaceuticals (NASDAQ:PTLA) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.41) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.46) by $0.05. Portola Pharmaceuticals had a negative net margin of 1,268.34% and a negative return on equity of 108.43%. The firm had revenue of $9.80 million during the quarter, compared to the consensus estimate of $3.71 million. During the same quarter in the prior year, the firm earned ($0.95) earnings per share. The business’s quarterly revenue was down 28.4% on a year-over-year basis. equities research analysts forecast that Portola Pharmaceuticals will post -4.91 EPS for the current fiscal year.

In other news, Director Henry Ward Wolff sold 12,000 shares of the stock in a transaction on Friday, December 15th. The shares were sold at an average price of $47.00, for a total transaction of $564,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 5.50% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Insider Buying and Selling by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with's FREE daily email newsletter.